Back

Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing Therapies

Pate, B.; Goldstein, A.; Labott, M.; Lizarralde-Iragorri, M.; Chankhunthod, A.; Tyson, T.; Sloan, M.; Wijeyesekera, C.; Wilks, A.; Steinberg, M. H.; Murphy, G. J.; Vanuytsel, K.

2026-05-21 cell biology
10.64898/2026.05.18.726003 bioRxiv
Show abstract

Sickle cell disease (SCD) is caused by a point mutation in the {beta}-globin gene that promotes hemoglobin polymerization, leading to chronic hemolytic anemia, vaso-occlusive episodes, and progressive organ damage. The most efficacious therapies focus on reactivating fetal hemoglobin (HbF) expression to mitigate the pathological effects of sickle hemoglobin (HbS) polymerization. However, the predominantly used HbF inducer, hydroxyurea (HU), exhibits substantial interpatient variability in efficacy, and curative approaches such as gene therapy remain inaccessible to the vast majority of patients. Although all SCD patients share the same causative HBB glu7val mutation, differences in genetic background significantly influence disease severity and therapeutic response. We describe a SCD-specific induced pluripotent stem cell (iPSC) platform as a renewable and scalable preclinical model to interrogate treatment responses across the genetically diverse SCD patient population. By generating patient-specific iPSC-derived erythroblasts (iEry) representing distinct SCD genetic backgrounds, we demonstrate that this system faithfully recapitulates the heterogeneous HbF induction observed clinically in response to HU. Moreover, this platform enables the identification and evaluation of alternative therapeutic agents for HU non-responders and provides sufficient resolution to dissect drug-specific effects on erythroid differentiation and cellular phenotypes. Together, these findings support the use of iPSC-derived erythroid models as a versatile tool to advance precision therapeutic strategies for SCD. KEY POINTS- SCD iPSC-derived erythroid cells (iEry) reflect the diversity in HU-mediated HbF induction seen in SCD patients - SCD iEry recapitulate patient-specific treatment responses and can be used to identify therapeutic alternatives for HU non-responders - iEry provide a versatile platform to study the impact of novel HbF inducers on erythroid cell characteristics and differentiation parameters

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Blood Advances
54 papers in training set
Top 0.1%
14.3%
2
Stem Cell Reports
118 papers in training set
Top 0.1%
6.8%
3
Scientific Reports
3102 papers in training set
Top 18%
6.3%
4
JCI Insight
241 papers in training set
Top 0.9%
4.3%
5
Blood
67 papers in training set
Top 0.4%
4.1%
6
eLife
5422 papers in training set
Top 26%
3.6%
7
Cell Reports Methods
141 papers in training set
Top 0.9%
3.6%
8
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.2%
3.6%
9
Cell Reports Medicine
140 papers in training set
Top 2%
3.2%
10
Haematologica
24 papers in training set
Top 0.2%
3.1%
50% of probability mass above
11
Stem Cell Research & Therapy
30 papers in training set
Top 0.2%
3.1%
12
Stem Cells
28 papers in training set
Top 0.1%
2.9%
13
Nature Communications
4913 papers in training set
Top 45%
2.6%
14
Cytotherapy
14 papers in training set
Top 0.1%
2.4%
15
PLOS ONE
4510 papers in training set
Top 45%
2.4%
16
British Journal of Haematology
15 papers in training set
Top 0.2%
2.1%
17
Cell Reports
1338 papers in training set
Top 24%
1.7%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 33%
1.7%
19
iScience
1063 papers in training set
Top 15%
1.7%
20
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 4%
1.7%
21
Stem Cells Translational Medicine
11 papers in training set
Top 0.1%
1.7%
22
Frontiers in Genetics
197 papers in training set
Top 7%
0.9%
23
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.4%
0.9%
24
Communications Biology
886 papers in training set
Top 19%
0.9%
25
Experimental Hematology
11 papers in training set
Top 0.2%
0.8%
26
Neurobiology of Disease
134 papers in training set
Top 4%
0.7%
27
Stem Cell Research
16 papers in training set
Top 0.1%
0.7%
28
Journal of Biological Chemistry
641 papers in training set
Top 4%
0.7%
29
Molecular Therapy
71 papers in training set
Top 3%
0.7%
30
PLOS Genetics
756 papers in training set
Top 17%
0.6%